Respiratory Syncytial Virus Infections in Infants Affected by Primary Immunodeficiency

Abstract EN

Primary immunodeficiencies are rare inherited disorders that may lead to frequent and often severe acute respiratory infections.

Respiratory syncytial virus (RSV) is one of the most frequent pathogens during early infancy and the infection is more severe in immunocompromised infants than in healthy infants, as a result of impaired T- and B-cell immune response unable to efficaciously neutralize viral replication, with subsequent increased viral shedding and potentially lethal lower respiratory tract infection.

Several authors have reported a severe clinical course after RSV infections in infants and children with primary and acquired immunodeficiencies.

Environmental prophylaxis is essential in order to reduce the infection during the epidemic season in hospitalized immunocompromised infants.

Prophylaxis with palivizumab, a humanized monoclonal antibody against the RSV F protein, is currently recommended in high-risk infants born prematurely, with chronic lung disease or congenital heart disease.

Currently however the prophylaxis is not routinely recommended in infants with primary immunodeficiency, although some authors propose the extension of prophylaxis to this high risk population.